Clinical Trials for Advanced Solid Tumor Cancers
Immunolight Cancer Therapy:
A Non-Chemotherapy Clinical Trial for Advanced Solid Tumors
Immunolight has developed what we believe will be a paradigm shift in the treatment of cancer. Cancer remains a very significant medical, emotional and financial burden on society. Our highest priority at Immunolight is to translate innovations in energy conversion, our core technology, into developing new possibilities for therapies to treat cancer.
2026 Expansion Cohorts
We’re excited to announce the expansion of our Phase I Clinical Trial to include Triple Negative Breast Cancer (TNBC) and Soft Tissue Sarcoma (STS) cohorts. The expanded cohorts include the potential to treat 16 patients in each group. In conjunction with these expanded cohorts, we are continuing to recruit and treat patients with other advanced solid tumors. More information on the study can also be found at ClinicalTrials.gov.
FiRe Conference 2025
Rick Bourke, founder and CEO of Immunolight, explains the latest advancements in the technology and how it’s used in the fight against cancer as well as how it could potentially impact a number of industries. Watch the latest Future in Review (FiRe) episode to understand more about Immunolight Cancer Therapy (ICT). Bourke shares insights into the development of this new treatment, how it works, and its potential to revolutionize treatment for patients worldwide.
Harnessing the Power of Light
Tune into the latest Future in Review (FiRe) podcast episode with Berit Anderson, COO of FiRe, and Harold Walder, President of Immunolight, to discuss the innovative Immunolight Cancer Therapy (ICT). Walder will share insights into the development of this groundbreaking treatment.